Poveda Cristina, Leão Ana Carolina, Mancino Chiara, Taraballi Francesca, Chen Yi-Lin, Adhikari Rakesh, Villar Maria Jose, Kundu Rakhi, Nguyen Duc M, Versteeg Leroy, Strych Ulrich, Hotez Peter J, Bottazzi Maria Elena, Pollet Jeroen, Jones Kathryn M
Department of Pediatrics, Division of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA.
Texas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
Curr Res Immunol. 2023 Jul 20;4:100066. doi: 10.1016/j.crimmu.2023.100066. eCollection 2023.
Tc24 is a derived flagellar protein that, when formulated with a TLR-4 agonist adjuvant, induces a balanced immune response in mice, elevating IgG2a antibody titers and IFN-γ levels. Furthermore, vaccination with the recombinant Tc24 protein can reduce parasite levels and improve survival during acute infection. Although some mRNA vaccines have been proven to elicit a stronger immune response than some protein vaccines, they have not been used against . This work evaluates the immunogenicity of a heterologous prime/boost vaccination regimen using protein and mRNA-based Tc24 vaccines. Mice (C57BL/6) were vaccinated twice subcutaneously, three weeks apart, with either the Tc24-C4 protein + glucopyranosyl A (GLA)-squalene emulsion, Tc24 mRNA Lipid Nanoparticles, or with heterologous protein/mRNA or mRNA/protein combinations, respectively. Two weeks after the last vaccination, mice were euthanized, spleens were collected to measure antigen-specific T-cell responses, and sera were collected to evaluate IgG titers and isotypes. Heterologous presentation of the Tc24 antigen generated antigen-specific polyfunctional CD8 T cells, a balanced Th1/Th2/Th17 cytokine profile, and a balanced humoral response with increased serum IgG, IgG1 and IgG2c antibody responses. We conclude that heterologous vaccination using Tc24 mRNA to prime and Tc24-C4 protein to boost induces a broad and robust antigen-specific immune response that was equivalent or superior to two doses of a homologous protein vaccine, the homologous mRNA vaccine and the heterologous Tc24-C4 Protein/mRNA vaccine.
Tc24是一种衍生的鞭毛蛋白,当与TLR-4激动剂佐剂配制时,可在小鼠体内诱导平衡的免疫反应,提高IgG2a抗体滴度和IFN-γ水平。此外,用重组Tc24蛋白进行疫苗接种可降低寄生虫水平并提高急性感染期间的存活率。尽管一些mRNA疫苗已被证明比一些蛋白质疫苗能引发更强的免疫反应,但它们尚未用于对抗…… 这项工作评估了使用基于蛋白质和mRNA的Tc24疫苗的异源初免/加强疫苗接种方案的免疫原性。小鼠(C57BL/6)分别皮下接种两次,间隔三周,分别接种Tc24-C4蛋白+吡喃葡萄糖基A(GLA)-角鲨烯乳剂、Tc24 mRNA脂质纳米颗粒,或异源蛋白/mRNA或mRNA/蛋白组合。最后一次接种后两周,对小鼠实施安乐死,收集脾脏以测量抗原特异性T细胞反应,并收集血清以评估IgG滴度和亚型。Tc24抗原的异源呈递产生了抗原特异性多功能CD8 T细胞、平衡的Th1/Th2/Th17细胞因子谱,以及血清IgG、IgG1和IgG2c抗体反应增加的平衡体液反应。我们得出结论,使用Tc24 mRNA初免和Tc24-C4蛋白加强的异源疫苗接种可诱导广泛而强大的抗原特异性免疫反应,该反应等同于或优于两剂同源蛋白疫苗、同源mRNA疫苗和异源Tc24-C4蛋白/mRNA疫苗。